Abortion in Second Trimester Clinical Trial
Official title:
Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Armenia
The primary goal of this study is to examine the efficacy and feasibility of a mifepristone combined with misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Armenia.
Women who were deemed eligible for the study by the provider gave informed consent. They took 200 mg of mifepristone orally at the study clinic. In 24-44 hours, they returned to the clinic for induction with misoprostol. They were admitted as inpatients at the clinic and took 400 mcg of buccal misoprostol every 3 hours until the fetus and placenta were expelled. If there was no full expulsion after 10 doses of misoprostol, the provider used their discretion to determine the appropriate clinical course of action. After responding to questions about their experience with the procedure, women were discharged from the study. ;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02235155 -
Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan
|
N/A | |
| Completed |
NCT03710239 -
OPIOID Study - Pain With Osmotic Dilators
|
N/A | |
| Completed |
NCT05046041 -
Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal
|
Phase 4 | |
| Completed |
NCT03346629 -
Outpatient Service for Mid-trimester Termination of Pregnancy
|
Phase 4 |